BR9705117A - Lipídeos catiônicos para terapia de gene - Google Patents
Lipídeos catiônicos para terapia de geneInfo
- Publication number
- BR9705117A BR9705117A BR9705117A BR9705117A BR9705117A BR 9705117 A BR9705117 A BR 9705117A BR 9705117 A BR9705117 A BR 9705117A BR 9705117 A BR9705117 A BR 9705117A BR 9705117 A BR9705117 A BR 9705117A
- Authority
- BR
- Brazil
- Prior art keywords
- gene therapy
- cationic lipids
- lipids
- cationic
- therapy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2958196P | 1996-10-22 | 1996-10-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9705117A true BR9705117A (pt) | 1998-09-15 |
Family
ID=21849783
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9705117A BR9705117A (pt) | 1996-10-22 | 1997-10-22 | Lipídeos catiônicos para terapia de gene |
Country Status (7)
Country | Link |
---|---|
US (1) | US6034137A (pt) |
EP (1) | EP0846680A1 (pt) |
JP (1) | JPH10152461A (pt) |
CN (1) | CN1068585C (pt) |
AR (1) | AR010013A1 (pt) |
BR (1) | BR9705117A (pt) |
CA (1) | CA2217550A1 (pt) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5674908A (en) | 1993-12-20 | 1997-10-07 | Life Technologies, Inc. | Highly packed polycationic ammonium, sulfonium and phosphonium lipids |
US6989434B1 (en) | 1994-02-11 | 2006-01-24 | Invitrogen Corporation | Reagents for intracellular delivery of macromolecules |
US6395713B1 (en) * | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
WO2000027795A1 (en) | 1998-11-12 | 2000-05-18 | Invitrogen Corporation | Transfection reagents |
FR2788275B1 (fr) * | 1999-01-11 | 2002-06-14 | Lipha | ((aminoiminomethyl)amino) alcane carboxamides et leurs applications en therapeutique |
US7294511B2 (en) * | 2001-03-22 | 2007-11-13 | Chromos Molecular Systems, Inc. | Methods for delivering nucleic acid molecules into cells and assessment thereof |
US20030096414A1 (en) | 2001-03-27 | 2003-05-22 | Invitrogen Corporation | Culture medium for cell growth and transfection |
WO2003106701A1 (es) * | 2002-06-01 | 2003-12-24 | Consejo Superior De Investigaciones Científicas | Detección y análisis no invasivo de microorganismos en productos lácteos en envases laminados de papel o cartón utilizando ondas elásticas por acoplamiento en seco. |
GB0315783D0 (en) * | 2003-07-04 | 2003-08-13 | Norferm Da | Use |
JP5166022B2 (ja) | 2004-05-05 | 2013-03-21 | サイレンス・セラピューティクス・アーゲー | 脂質、脂質複合体、およびその使用 |
EP1793865A4 (en) * | 2004-08-05 | 2009-05-13 | Baylor Res Inst | GENETIC OR DRUG DELIVERY SYSTEM |
BRPI0519468A2 (pt) | 2004-12-27 | 2009-01-27 | Silence Therapeutics Ag | complexos de lipÍdeos revestido e seu uso |
DE602005024794D1 (de) | 2005-07-22 | 2010-12-30 | Novagali Pharma Sa | Verfahren zur Herstellung von gesättigten und ungesättigten primären Fett-Aminen |
WO2008009477A2 (en) | 2006-07-21 | 2008-01-24 | Silence Therapeutics Ag | Means for inhibiting the expression of protein kinase 3 |
CA2664632A1 (en) * | 2006-09-27 | 2008-04-03 | Paolo Botti | Means and methods of enhancing delivery to biological systems |
WO2009138806A1 (en) * | 2008-05-13 | 2009-11-19 | Dendrigen S.A. | Novel liposome cocktail formulations containing doxorubicin and the potent multidrug resistance inhibitor amiodarone |
CA2724408A1 (en) * | 2008-05-19 | 2009-11-26 | The University Of North Carolina At Chapel Hill | Methods and compositions comprising novel cationic lipids |
JP5889783B2 (ja) * | 2009-05-05 | 2016-03-22 | テクミラ ファーマシューティカルズ コーポレイションTekmira Pharmaceuticals Corporation | 免疫細胞へオリゴヌクレオチドを送達する方法 |
BR212012000255U2 (pt) * | 2009-07-09 | 2015-11-03 | Marina Biotech Inc | lipossomas anfotéricos compreendendo imino lípidos. |
EP2567951B1 (en) * | 2010-04-28 | 2018-09-19 | Kyowa Hakko Kirin Co., Ltd. | Cationic lipid |
EP2640700B1 (en) | 2010-11-15 | 2018-10-31 | Life Technologies Corporation | Amine-containing transfection reagents and methods for making and using same |
EP2532649B1 (en) * | 2011-06-07 | 2015-04-08 | Incella GmbH | Amino lipids, their synthesis and uses thereof |
JP6182457B2 (ja) * | 2011-12-12 | 2017-08-16 | 協和発酵キリン株式会社 | カチオン性脂質を含有するドラックデリバリーシステムのための脂質ナノ粒子 |
EP2792368A4 (en) * | 2011-12-12 | 2015-09-30 | Kyowa Hakko Kirin Co Ltd | LIPID NANOPARTICLES WITH COMBINATIONS OF CATIONIC LIPIDES |
EP2934563B1 (en) * | 2012-12-18 | 2020-07-08 | Jawaharlal Nehru Centre for Advanced Scientific Research | Antimicrobial compounds, their synthesis and applications thereof |
PL3766916T3 (pl) | 2014-06-25 | 2023-02-27 | Acuitas Therapeutics Inc. | Nowe lipidy i formulacje nanocząstek lipidowych do dostarczania kwasów nukleinowych |
WO2016011203A1 (en) | 2014-07-15 | 2016-01-21 | Life Technologies Corporation | Compositions with lipid aggregates and methods for efficient delivery of molecules to cells |
WO2016045732A1 (en) * | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
WO2016108634A2 (ko) | 2014-12-30 | 2016-07-07 | (주)셀트리온 | 표피성장인자와 리포좀의 하이브리드형 다중층 나노구조체 및 그 제조방법 |
PT3313829T (pt) | 2015-06-29 | 2024-07-08 | Acuitas Therapeutics Inc | Formulações de lípidos e de nanopartículas lipídicas para a administração de ácidos nucleicos |
WO2017075531A1 (en) | 2015-10-28 | 2017-05-04 | Acuitas Therapeutics, Inc. | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
WO2018191657A1 (en) | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
CA3061612A1 (en) | 2017-04-28 | 2018-11-01 | Acuitas Therapeutics, Inc. | Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids |
US11639329B2 (en) | 2017-08-16 | 2023-05-02 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
WO2019036030A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS |
US11542225B2 (en) | 2017-08-17 | 2023-01-03 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
WO2019036000A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS |
JP7543259B2 (ja) * | 2018-10-18 | 2024-09-02 | アクイタス セラピューティクス インコーポレイテッド | 活性剤の脂質ナノ粒子送達のための脂質 |
KR20210138569A (ko) | 2019-01-11 | 2021-11-19 | 아퀴타스 테라퓨틱스 인크. | 활성제의 지질 나노입자 전달을 위한 지질 |
CN111087332B (zh) * | 2019-12-11 | 2021-07-06 | 东南大学 | 一种阳离子氨基脂质及其合成方法与应用 |
AU2021308681A1 (en) | 2020-07-16 | 2023-03-09 | Acuitas Therapeutics, Inc. | Cationic lipids for use in lipid nanoparticles |
CA3143650A1 (en) * | 2021-12-22 | 2023-06-22 | Providence Therapeutics Holdings Inc. | Lipids and compositions thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4926046B1 (pt) * | 1969-12-30 | 1974-07-05 | ||
DE2808943A1 (de) * | 1978-03-02 | 1979-09-06 | Goldschmidt Ag Th | Neue guanidiniumsalze, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende mikrobicide zubereitungen |
JPS5754157A (en) * | 1980-09-19 | 1982-03-31 | Nippon Kayaku Co Ltd | L-argininal derivative and its preparation |
US4477428A (en) * | 1982-08-26 | 1984-10-16 | Johnson & Johnson Products, Inc. | Oral compositions comprising N.sup.α,NG -diacyl derivatives of arginine |
GB8312663D0 (en) * | 1983-05-09 | 1983-06-15 | Ici Plc | Bisbiguanide compounds |
GB8312662D0 (en) * | 1983-05-09 | 1983-06-15 | Ici Plc | Polyether bisbiguanide |
JPS60214768A (ja) * | 1984-04-07 | 1985-10-28 | Fujisawa Pharmaceut Co Ltd | オリゴペプチド化合物 |
US5141751A (en) * | 1988-06-29 | 1992-08-25 | Daiichi Pharmaceutical Co., Ltd. | Lipid membrane structures |
US5478946A (en) * | 1989-06-21 | 1995-12-26 | Abbott Laboratories | Guanidino compounds as regulators of nitric oxide synthase |
US5654451B1 (en) * | 1993-01-14 | 2000-02-22 | Magainin Pharma | Amino acids and peptides having modified c-terminals and modified n-terminals |
EP0679153A4 (en) * | 1993-01-14 | 1996-05-15 | Magainin Pharma | FINALLY MODIFIED AMINO ACIDS AND PEPTIDES. |
JPH07136604A (ja) * | 1993-11-24 | 1995-05-30 | Ebara Corp | 洗浄方法及び装置 |
NZ276975A (en) * | 1993-11-24 | 1998-04-27 | Megabios Corp | Guanidine based amphiphiles and their use in liposomes for delivering genetic material intracellularly |
WO1995028377A1 (en) * | 1994-04-18 | 1995-10-26 | Abbott Laboratories | Guanidine compounds as regulators of nitric oxide synthase |
US5777153A (en) * | 1994-07-08 | 1998-07-07 | Gilead Sciences, Inc. | Cationic lipids |
US5830430A (en) * | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
JP3163230B2 (ja) * | 1995-03-13 | 2001-05-08 | 科学技術振興事業団 | 二次元分子パターンの作成方法 |
-
1997
- 1997-10-07 CA CA002217550A patent/CA2217550A1/en not_active Abandoned
- 1997-10-16 EP EP97117934A patent/EP0846680A1/en not_active Withdrawn
- 1997-10-20 AR ARP970104853A patent/AR010013A1/es not_active Application Discontinuation
- 1997-10-20 US US08/954,428 patent/US6034137A/en not_active Expired - Fee Related
- 1997-10-20 JP JP9285925A patent/JPH10152461A/ja active Pending
- 1997-10-21 CN CN97121514A patent/CN1068585C/zh not_active Expired - Fee Related
- 1997-10-22 BR BR9705117A patent/BR9705117A/pt unknown
Also Published As
Publication number | Publication date |
---|---|
MX9708111A (es) | 1998-08-30 |
CA2217550A1 (en) | 1998-04-22 |
JPH10152461A (ja) | 1998-06-09 |
CN1068585C (zh) | 2001-07-18 |
CN1180697A (zh) | 1998-05-06 |
AR010013A1 (es) | 2000-05-17 |
US6034137A (en) | 2000-03-07 |
EP0846680A1 (en) | 1998-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9705117A (pt) | Lipídeos catiônicos para terapia de gene | |
DE69815075D1 (de) | Dimere kationische lipide auf dicystinbasis | |
BR9612533A (pt) | Terapia de combinação para osteoporose | |
DE69735382D1 (de) | Kationische reagenzien zür transfektion | |
PT849853E (pt) | Consola para calhas de suporte | |
EP1015578A4 (en) | THERAPEUTIC MOLECULES | |
ID24118A (id) | Terapi gabungan | |
NO20004688D0 (no) | Terapi ved østrogenassosierte lidelser | |
BR9605819A (pt) | Apoio para cabeça | |
ID24275A (id) | Terapi kombinasi | |
NO970172D0 (no) | Kationiske amfifiler | |
PT907358E (pt) | Terapia de distribuicao uniforme de droga | |
EP1007028A4 (en) | TREATING GLAUCOMA WITH 8 ISO PROSTAGLANDINE | |
PT9493U (pt) | Cabeca para esfregona | |
NO20006047D0 (no) | Fremgangsmåte for genterapi | |
EP1037631A4 (en) | HETEROCYCLIC CATIONIC FATS | |
BR9508281A (pt) | Técnica para autenticação | |
BR9500251A (pt) | Multi-contador para rodas | |
BR9700690A (pt) | Banco para terapia neurológica | |
ES1031699Y (es) | Envase para golosinas | |
BR9704122A (pt) | Estimulador eletro-eletrônico para seios | |
BR9705606A (pt) | Luminária para cromoterapia | |
BR9505158A (pt) | Complexo inorgânico para tratamento de tumores | |
BR7701696U (pt) | Disposição em suporte para fixação de rodízio | |
ES1029754Y (es) | Base para enchufe electrico de seguridad. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8A ANUIDADES. |